<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310296</url>
  </required_header>
  <id_info>
    <org_study_id>USWM-LX1-1003/ 02749MZ</org_study_id>
    <nct_id>NCT01310296</nct_id>
  </id_info>
  <brief_title>Lofexidine ADME &amp; Mass Balance in Volunteers</brief_title>
  <official_title>A Single-Center, Open-Label, Two-Period, Two-Treatment, Randomized Sequence Study to Determine the Mass Balance and Absolute Bioavailability of a Single Oral Dose of 14C-Labeled Lofexidine Compared to a Single Intravenous Dose of Lofexidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US WorldMeds LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>US WorldMeds LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the mass balance and absolute bioavailability of a&#xD;
      single oral dose of 14C-labeled lofexidine compared to a single intravenous dose of&#xD;
      lofexidine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance</measure>
    <time_frame>plasma, urine, and fecal samples up to 216 hours post dose</time_frame>
    <description>To determine the mass balance recovery of orally administered lofexidine hydrochloride</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Bioavailability &amp; Tolerability</measure>
    <time_frame>plasma samples over 72 and 144 hrs post-dose for IV and oral doses, respectively</time_frame>
    <description>To determine the absolute bioavailability of a single oral dose of lofexidine compared to a single intravenous dose of lofexidine&#xD;
To determine the tolerability of lofexidine oral solution and intravenous lofexidine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Normal Healthy Volunteers Will be Treated With Lofexidine to Understand the Absolute Bioavailability and Mass Balance Recovery of the Product</condition>
  <arm_group>
    <arm_group_label>Radiolabeled Lofexidine Oral Solution</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lofexidine Intravenous Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine hydrochloride</intervention_name>
    <description>Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine</description>
    <arm_group_label>Radiolabeled Lofexidine Oral Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine hydrochloride</intervention_name>
    <description>Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min</description>
    <arm_group_label>Lofexidine Intravenous Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be a male or non-pregnant, non-breastfeeding female.&#xD;
&#xD;
          -  Subject must be between 18 and 50 years of age (inclusive).&#xD;
&#xD;
          -  Subject's Body Mass Index (BMI) must be between 18 and 30 kg/m2 (inclusive), and&#xD;
             subject must weigh a minimum of 50 kg (110 lbs).&#xD;
&#xD;
          -  Female subjects must agree to use one of the following forms of birth control from&#xD;
             screening until 14 days after completion of the study:&#xD;
&#xD;
          -  Vasectomized partner (at least 6 months prior to dosing)&#xD;
&#xD;
          -  Post-menopausal (at least 2 years prior to dosing)&#xD;
&#xD;
          -  Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) at&#xD;
             least 6 months prior to dosing&#xD;
&#xD;
          -  Double barrier (diaphragm with spermicide; condoms with spermicide)&#xD;
&#xD;
          -  IUD (intra-uterine device)&#xD;
&#xD;
          -  Abstinence (must agree to use a double barrier method if they become sexually active&#xD;
             during the study)&#xD;
&#xD;
          -  Implanted or intrauterine hormonal contraceptives in use for at least 6 consecutive&#xD;
             months prior to study dosing and throughout the study duration&#xD;
&#xD;
          -  Oral, patch, and injected contraceptives or vaginal hormonal device (i.e. NuvaRing®)&#xD;
             in use for at least 3 consecutive months prior to study dosing and throughout the&#xD;
             study duration.&#xD;
&#xD;
          -  Subject must voluntarily consent to participate in this study and provide their&#xD;
             written informed consent prior to start of any study- specific procedures.&#xD;
&#xD;
          -  Subject is willing and able to remain in the study unit for the entire duration of&#xD;
             each confinement period.&#xD;
&#xD;
          -  Subject's vital signs must be within the following ranges to be included: Vital signs&#xD;
             measured sitting after 3 minutes rest; heart rate: 50-90 bpm; systolic BP: 100-140&#xD;
             mmHg; diastolic BP: 50-90 mmHg, and oral temperature within the normal range of&#xD;
             35.6-37.7° C. Out-of-range vital signs may be repeated once. Predose vital signs will&#xD;
             be assessed by the Principal Investigator or designee (e.g., a medically qualified&#xD;
             sub-investigator) prior to study drug administration. The Principal Investigator or&#xD;
             designee will verify the eligibility of each subject with out-of-range vital signs and&#xD;
             document approval prior to dosing.&#xD;
&#xD;
          -  For the study period in which the subject is assigned to receive Treatment A&#xD;
             (lofexidine oral solution containing 14C-lofexidine), subject must be:&#xD;
&#xD;
          -  Willing to eat entire meals and snacks provided during confinement at the research&#xD;
             facility; and understand that the diet will include foods with high fiber content and&#xD;
             possibly prune juice.&#xD;
&#xD;
          -  Willing to remain in the clinical research center for a minimum of 7 consecutive days&#xD;
             during pre-dose, dose, and post-dose evaluation periods. Subjects must be willing to&#xD;
             stay for an additional 24 to 48 hours if necessary.&#xD;
&#xD;
          -  Willing to collect all urine and fecal samples for the duration of the study period as&#xD;
             required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurologic, oncologic, or psychiatric disease or any other condition that, in the&#xD;
             opinion of the Investigator, would jeopardize the safety of the subject or the&#xD;
             validity of the study results.&#xD;
&#xD;
          -  Has a clinically significant abnormal finding on the physical exam, medical history,&#xD;
             ECG, or clinical laboratory results at screening.&#xD;
&#xD;
          -  History of any syncopal episode or seizures.&#xD;
&#xD;
          -  Presence of acute disease state (eg, nausea, vomiting, fever, diarrhea) within 7 days&#xD;
             prior to scheduled dose administration.&#xD;
&#xD;
          -  History or presence of allergic or adverse response to lofexidine or related drugs.&#xD;
&#xD;
          -  Has been on a significantly abnormal diet during the 4 weeks preceding the first dose&#xD;
             of study medication.&#xD;
&#xD;
          -  Has donated blood or plasma within 30 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Has participated in a radiolabeled clinical trial within the last 12 months prior to&#xD;
             the first dose of study medication.&#xD;
&#xD;
          -  Has participated in another clinical trial (randomized subjects only) within 30 days&#xD;
             prior to the first dose of study medication.&#xD;
&#xD;
          -  Has used any over-the-counter (OTC) medication, including nutritional supplements,&#xD;
             within 7 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Has used any prescription medication, except hormonal contraceptive or hormonal&#xD;
             replacement therapy, within 14 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Subjects that have discontinued the use of implanted, intrauterine, or injected&#xD;
             hormonal contraceptives must not have used any for 6 months prior to study start.&#xD;
&#xD;
          -  Subjects that have discontinued the use of oral, patch, or vaginal hormonal&#xD;
             contraceptives must not have used any for 1 month prior to study start.&#xD;
&#xD;
          -  Has been treated with any known drugs that are moderate or strong inhibitors/inducers&#xD;
             of CYP enzymes such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc.,&#xD;
             within 30 days prior to the first dose of study medication and that in the&#xD;
             Investigator's judgment may impact subject safety or the validity of the study&#xD;
             results.&#xD;
&#xD;
          -  Has smoked or used tobacco products within 60 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Has any prior history of substance abuse or treatment (including alcohol) within the&#xD;
             past 2 years.&#xD;
&#xD;
          -  Is a female with a positive pregnancy test result.&#xD;
&#xD;
          -  Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,&#xD;
             benzodiazepines, cocaine, cannabinoids, opiates).&#xD;
&#xD;
          -  Has had a positive test for, or has been treated for hepatitis B, hepatitis C, or&#xD;
             Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  Has orthostatic hypotension at screening defined as a drop in systolic blood pressure&#xD;
             ≥ 20 mmHg or a fall in diastolic blood pressure ≥ 10 mmHg following a 2 minute stand.&#xD;
             Out-of-range vital signs may be repeated once. Predose vital signs will be assessed by&#xD;
             the Principal Investigator or designee (e.g., a medically qualified sub-investigator)&#xD;
             prior to study drug administration. The Principal Investigator or designee will verify&#xD;
             the eligibility of each subject with out-of-range vital signs and document approval&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Subjects with a QTcB greater than 450 msec (males) or greater than 470 msec (females),&#xD;
             at screening obtained after 5 minutes rest in a supine position using the ECG machine&#xD;
             algorithm.&#xD;
&#xD;
          -  Has irregular bowel habits. (&quot;Irregular&quot; being defined for the purpose of this study&#xD;
             as NOT having a bowel movement at least every 2 days.)&#xD;
&#xD;
          -  Has been exposed to radiation, including dental or medical imaging such as x ray or&#xD;
             tomography, in the 6 months prior to dose administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Longstreth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US WorldMeds</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles W Gorodetzky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US WorldMeds</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Leibowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2011</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Normal Healthy Volunteers</keyword>
  <keyword>Mass Balance</keyword>
  <keyword>ADME</keyword>
  <keyword>Absolute Bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lofexidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

